Jones E, Jones J V, Woodbury J F
Department of Medicine, Dalhousie University, Victoria General Hospital, Halifax, NS, Canada.
J Rheumatol. 1991 Feb;18(2):195-8.
Eighty-six patients with rheumatoid arthritis treated with sulfasalazine were followed for 5 years, or until treatment was discontinued. At the end of 5 years, there was a 22% probability of successfully continuing treatment. Most adverse effects developed in the first 3 months of treatment. In 38 patients treatment was discontinued because of inefficacy. In 18 of these, a brief period of improvement was followed by clinical relapse. Twenty were regarded as having no useful response to sulfasalazine. The treatment continuation rate of 22% at 5 years is in marked contrast to the pessimistic longterm evaluations of second line drugs that have recently been reported.
86例接受柳氮磺胺吡啶治疗的类风湿性关节炎患者被随访了5年，或直至治疗中断。5年后，成功持续治疗的概率为22%。大多数不良反应出现在治疗的前3个月。38例患者因治疗无效而中断治疗。其中18例在短暂改善后出现临床复发。20例被认为对柳氮磺胺吡啶无有效反应。5年时22%的治疗持续率与最近报道的对二线药物的悲观长期评估形成了鲜明对比。
